NCT03904329 is a clinical trial of Oral Anticoagulant in Obesity Paradox, sponsored by Assiut University.

Who is sponsoring NCT03904329?

NCT03904329 is sponsored by Assiut University.

What drugs are being tested in NCT03904329?

Interventions in NCT03904329: Oral Anticoagulant.

What condition does NCT03904329 study?

NCT03904329 studies Obesity Paradox.

Is NCT03904329 still recruiting?

NCT03904329 is currently status unknown. Last updated 4 August 2022.

Last reviewed 2022-08-04 · How we verify

NCT03904329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction

Status unknown Last updated 4 August 2022

What this trial tests

trial testing Oral Anticoagulant in Obesity Paradox in 1 participant. Status unknown.

Timeline

1 October 2020

Primary endpoint
1 August 2023

1 October 2023

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1
Start date	1 October 2020
Primary completion	1 August 2023
Estimated completion	1 October 2023
Sites	1 location across Egypt

Drugs / interventions tested

Oral Anticoagulant (oral-anticoagulant) — full drug profile →

Conditions studied

Obesity Paradox — all drugs for Obesity Paradox →

Sponsor

Assiut University

Who can join

Adults 18 to 90, any sex, with Obesity Paradox. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity paradox In patient with non valvular atrial fibrillation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Obesity paradox in patients with non -valvular atrial fibrillation regarding outcomes; fact or fiction?
Abdelsabour M, Bakhet CA, Atta S. · · 2023 · DOI 10.21203/rs.3.rs-2472503/v1

Verify or expand the search:

Other trials of Oral Anticoagulant

Trials testing the same drug.

NCT03558295 — CHAOS Registry Study · unknown
NCT03062319 — Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis · Phase 4 · terminated
NCT03292666 — Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study · completed

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03904329 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 4 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03904329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing